Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Markets Set New Record Closes; FedEx Beats on Q2 (revised)
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $38.03, moving +0.5% from the previous trading session.
Markets Set New Record Closes; FedEx Beats on Q2
by Mark Vickery
It's the S&P 500's 31st all-time closing high this year, and Nasdaq is on pace for its strongest full-year performance since 2009.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
10 Best Performing Leveraged ETFs of 2020
by Sweta Killa
This year has witnessed historic twists and turns with the largest bull market turning into a bear market in March on the coronavirus outbreak, and then marking the fastest-ever recovery.
5 Beaten-Down Energy Stocks to Buy for a Turnaround in 2021
by Nilanjan Choudhury
With energy set for a strong 2021 on vaccine-led demand boost, 5 underperformers of this year - DCP Midstream (DCP), Sinopec (SNP), Vermilion Energy (VET), NOW (DNOW) and Enerplus (ERF) - are likely to rebound.
These Stocks Could Be Your Secret Santa This Christmas
by Sweta Killa
Looking for a surprise this Christmas? Bet on these stocks - BJs Wholesale (BJ), Gogo (GOGO), TRI Pointe (TPH), Penske Automotive (PAG), and Santander Consumer (SC) - for big returns.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study
by Zacks Equity Research
CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Trane Technologies, United Parcel Service, FedEx and Moderna
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
6 Secret Santa ETFs to Add Cheer to Your Portfolio
by Sweta Killa
While most of the ETFs have been surging over the past month, there are some hidden gems or Secret Santa as we call them that could surprise investors with big returns this Christmas based on the current trends.
Stock Market News for Dec 16, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Tuesday buoyed by investors' renewed hopes for a fresh round of coronavirus-aid package by this week end.
Earn 7% Plus Yield With These ETFs
by Sanghamitra Saha
These ETFs offer at least 7% in annual yield.
5 Small-Cap Sector ETFs Beating the Russell 2000
by Sweta Killa
We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.
Industrial Production Beats Expectations in November
by Zacks Equity Research
Industrial Production Beats Expectations in November.
Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout
by Sweta Killa
The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.
Markets Swing Back Up on Vaccine Positivity
by Mark Vickery
Import Prices, Empire State and Industrial Production numbers join new positive data from the FDA on Moderna's (MRNA) vaccine candidate.
Stock Market News for Dec 15, 2020
by Zacks Equity Research
Wall Street closed mixed on Monday as investors remained concerned about recent spike in new COVID-19 cases in the United States and Eurozone.
AstraZeneca's (AZN) Triple Combo COPD Therapy Gets EU Nod
by Zacks Equity Research
AstraZeneca (AZN) gets European approval for triple combination therapy, Trixeo Aerosphere for COPD. CHMP recommends approval of trastuzumab deruxtecan for breast cancer.
Gaming ETF (BJK) Hits a New 52-Week High
by Sweta Killa
This gaming ETF hits a new 52-week high. Are more gains in store for this ETF?
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.